Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

BACKGROUND: We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in the Dutch daily practice as opposed to the results based on trial data and based on a subset of patients that were treated accordi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Seferina, Shanly C., Ramaekers, Bram L.T., de Boer, Maaike, Dercksen, M. Wouter, van den Berkmortel, Franchette, van Kampen, Roel J.W., van de Wouw, Agnès J., Voogd, Adri C., Tjan Heijnen, Vivianne C.G., Joore, Manuela A.
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Clinical Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5668034/
https://ncbi.nlm.nih.gov/pubmed/29108301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16985
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы